Independent, International and Industry-leading

Medix Biochemica is a market-leading in vitro diagnostics raw material supplier with Finnish roots and global branches. We produce and supply high-quality antibodies, antigens and other critical IVD raw materials to enable our IVD customers to manufacture diagnostic tests and supporting materials all around the world. Our expertise covers market segments from immunoassay, clinical chemistry and molecular diagnostics. Our capabilities include biospecimen accruals and contract manufacturing. With the most comprehensive raw material portfolio in the IVD world, and a team made up of the best minds in the business, we’re ready to shorten your time to market and build quality into every one of your tests. Across disciplines and disease areas, whatever you need, chances are we IVDo that.

Discover who we are

Learn about our history, our global impact and our IVD experts.

Through a series of strategic acquisitions, portfolio expansions and other activities, we are well on our way to becoming the first-choice raw material partner for the IVD industry. Learn more about our history here.

Get to grips with our products

Our comprehensive portfolio offers a wide selection of high-quality antibodies, native and recombinant antigens, biospecimen materials, and molecular diagnostic reagents to support several clinical areas of interest. Find out more here.

Find out what we IVDo
A partnership with Medix Biochemica comes with;

  • Consolidated supplier management
  • Access to quality products, on time delivery, at the scale needed
  • Industry knowledge and insight
  • Available technical expertise
  • Freeing up time and resources - for our customers to dedicate to what matters most to them

Medix Biochemica Group video

We’ve got offices and manufacturing facilities all around the world

Image Placeholder (22)
Marker
St. Louis, MO, USA
Marker
Weston, FL, USA
Marker
Espoo, Finland
Marker
Besançon, France
Marker
Konstanz, Germany
Marker
Shanghai, China
Marker
Westbrook, ME, USA

Meet Our Team Members

Our industry-leading IVD experts have decades of experience in the development of essential raw materials for diagnostic application. Meet some of our employees.

vincent-chen_220x286
Vincent Chen
Vice President & General Manager Commercial Operations China
I work for Medix Biochemica across China (including mainland, Hong kong, Taiwan and Macau), as well as being part of the global team. What energizes me about working here is being part of a team that's developing and constantly achieving.
Petra_Tuomiranta
Petra Tuomiranta
R&D Scientist
As an R&D scientist at Medix Biochemica, I am driven by the science of developing new monoclonal antibodies. I actively engage in formulating and guiding my own product development projects, guiding them from inception to the refined, finished products. The breadth of my role constantly fuels my enthusiasm, presenting a landscape of possibilities for continual learning and growth.
Matt Dobbs
Matt Dobbs
Production Chemist
My main role is to purify raw materials to meet our final product specifications. I help Medix Biochemica in succeeding by ensuring quality product is produced in a reliable, repeatable, and well documented manner on time. The variation of different products I purify, and the various methods used for the targeted product purity make my job exciting.
icon_join_the_team
This could be you
Join us on our mission to make a difference – we enable IVD customers to deliver accurate results to billions of patients!
1985
Monoclonal antibodies on an industrial scale
Medix Biochemica founded in Finland
2016
Local service for the Chinese IVD industry
Medix Biochemica China established
2018
Local service for North American customers
Medix Biochemica USA established
2019
World-leading products and expertise on native proteins
Lee Biosolutions acquired
2020
Radically more antibodies and antigens, especially for drugs of abuse and veterinary and infectious deseases testing
EastCoast Bio and Biostride acquired
2021
Kickstarted molecular diagnostics offering, plus unique antibodies and assays for immuno-oncology and inflammation
MedixMDx estabished and Diaclone acquired
2022
Extending our diagnostics offering and broadening our base matrix capabilities
myPOLS Biotec & Bioresource Technology acquired
2023
Expansion of infectious diseases product offering
Virostat acquired